← Eichor
Condition: Cd19 Positive Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Cd19 Positive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
NA · 1 location(s) · King Hussein Cancer Center · NCT07371403Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Phil
EARLY_Phase 1 · 2 location(s) · The First Affiliated Hospital of Soochow University · NCT07074496CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Phase 1 · 1 location(s) · Guangzhou Women and Children's Medical Center · NCT06752785CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Phase 1/Phase 2 · 1 location(s) · Affiliated Hospital to Academy of Military Medical Sciences · NCT06834529CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Phase 3 · 1 location(s) · Peking University People's Hospital · NCT07441291A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic
Phase 1 · 8 location(s) · Autolus Limited · NCT06173518Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
Phase N/A · 1 location(s) · N.N. Alexandrov National Cancer Centre · NCT07524816A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06287528Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Phase 2 · 3 location(s) · Sun Yat-sen University · NCT07077512Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 · 11 location(s) · Juventas Cell Therapy Ltd. · NCT04684147CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
Phase 2 · 1 location(s) · St. Jude Children's Research Hospital · NCT06847269GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Phase 1/Phase 2 · 1 location(s) · Grit Biotechnology · NCT06948981Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
Phase 1/Phase 2 · 11 location(s) · University Hospital Tuebingen · NCT05366218CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Phase 1/Phase 2 · 3 location(s) · Ottawa Hospital Research Institute · NCT03765177Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malign
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT07312630Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL
Phase 2 · 1 location(s) · King Hussein Cancer Center · NCT07271121Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
Phase 2 · 1 location(s) · West Virginia University · NCT07222579Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
Phase 1 · 1 location(s) · St. Jude Children's Research Hospital · NCT04881240Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT07429461Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06247501A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-p
EARLY_Phase 1 · 2 location(s) · Grit Biotechnology · NCT07205315CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/L
NA · 2 location(s) · Zhu Xiaofan · NCT06355739CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukem
Phase 1 · 1 location(s) · King Faisal Specialist Hospital & Research Center · NCT07361029GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
Phase 1 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06875063CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
NA · 1 location(s) · Hong Kong Children's Hospital · NCT06866873Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Phase 2 · 1 location(s) · University of Florida · NCT05800210UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
EARLY_Phase 1 · 1 location(s) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. · NCT06092047Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT07620314CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Phase 2 · 1 location(s) · Beijing Yongtai Ruike Biotechnology Company Ltd · NCT06179524Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1 · 1 location(s) · CytoCares Inc · NCT06037018
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.